Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: Three multicenter phase III studies

Pediatric Infectious Disease Journal

Volumn 31, Issue 11, 2012, Pages 1173-1183

  Pina, L Miriam ^a   Bassily, Ehab ^a   MacHmer, Agnes ^a   Hou, Victor ^a   Reinhardt, Albert ^a  

^a SANOFI PASTEUR   (France)

Author keywords

conjugate vaccine; immunogenicity; meningococcal; safety

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; DIPHTHERIA VACCINE; MENINGOCOCCAL POLYSACCHARIDE DIPHTHERIA TOXOID CONJUGATE VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CHICKENPOX; DIPHTHERIA; DRUG SAFETY; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; MEASLES; MENINGOCOCCOSIS; MULTICENTER STUDY (TOPIC); MUMPS; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RUBELLA; UNSPECIFIED SIDE EFFECT; VACCINATION;

DIPHTHERIA TOXOID; HUMANS; INFANT; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 84867855970     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318268dfe4     Document Type: Article

References (43)

1. Granoff DM, Harrison D, Borrow R. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 5th ed. Philadelphia, PA: Saunders Elsevier; 2008: 399-434
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(suppl 2):B51-B63.
3. Cohn AC, MacNeil JR, Harrison LH, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50:184-191.
4. Centers for Disease Control and Prevention. Meningococcal vaccines: what you need to know. Available at: http://www.cdc.gov/vaccines/pubs/vis/downloads/ vis-mening.pdf. Accessed April 26, 2012.
5. Centers for Disease Control and Prevention. Meningococcal disease: epidemiology and prevention of vaccine-preventable diseases. The Pink Book: Course Textbook. 12th ed. Atlanta, GA: Centers for Disease Control and Prevention; 2012. Available at: http://wwwcdc.gov/vaccines/pubs/pinkbook/ downloads/mening.pdf. Accessed April 26, 2012.
6. Kirsch EA, Barton RP, Kitchen L, et al. Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr Infect Dis J. 1996;15:967-978; quiz 979.
7. Wilder-Smith A, Goh KT, Barkham T, et al. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis. 2003;36:679-683. (Pubitemid 36337970)
8. Pollard AJ, Scheifele D. Meningococcal disease and vaccination in North America. J Paediatr Child Health. 2001;37:S20-S27. (Pubitemid 32989607)
9. Wilder-Smith A. Meningococcal vaccines: a neglected topic in travel medicine? Expert Rev Vaccines. 2009;8:1343-1350.
10. Efron AM, Sorhouet C, Salcedo C, et al. W135 invasive meningococcal strains spreading in South America: significant increase in incidence rate in Argentina. J Clin Microbiol. 2009;47:1979-1980.
11. Doyle TJ, Mejia-Echeverry A, Fiorella P, et al. Cluster of serogroup W135 meningococci, southeastern Florida, 2008-2009. Emerg Infect Dis. 2010;16:113-115.
12. Keyserling HL, Pollard AJ, DeTora LM, et al. Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Rev Vaccines. 2006;5:445-459. (Pubitemid 44627876)
13. Pace D, Pollard AJ, Messonier NE. Quadrivalent meningococcal conjugate vaccines. Vaccine. 2009;27(suppl 2):B30-B41.
14. Food and Drug Administration Web Site. January 14, 2005 approval letter. Available at: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ ApprovedProducts/ucm131181.htm. Accessed December 13, 2011.
15. Food and Drug Administration Web Site. FDA approves the first vaccine to prevent meningococcal disease in infants and toddlers. 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm252392.htm. Accessed December 13, 2011.
16. Cohn AC. Optimizing the adolescent meningococcal vaccination program. Available at: www.cdc.gov/vaccines/ed/ciinc/downloads/Dec-10/Cohn. pptx. Accessed December 13, 2011.
17. MENVEO® [prescribing information]. Cambridge, MA: Novartis Vaccines and Diagnostics, Inc. Available at: https://www.novartisvaccinesdirect.com/PDF/ Menveo-Full-Promotional-PI.pdf. Accessed April 30, 2012.
18. Centers for Disease Control and Prevention. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2011;60:72-76.
19. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-1326.
20. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med. 1969;129:1327-1348.
21. U.S. National Institutes of Health (NIH) Web Site. A study of 2 doses of Menactra®, a meningococcal conjugate vaccine in healthy toddlers. Available at: http://clinicaltrial.gov/ct2/show/NCT00384397?term=MTA44&rank=1. Accessed December 16, 2011.
22. U.S. National Institutes of Health (NIH) Web Site. Immunogenicity and safety of pediatric vaccines when administered with Menactra® in healthy toddlers. http://clinicaltrials.gov/ct2/show/NCT00422292?term=MTA37&rank=1. Accessed June 6, 2012.
23. U.S. National Institutes of Health (NIH) Web Site. Study of the safety of Menactra® when administered with other pediatric vaccines to healthy toddlers. http://clinicaltrial.gov/ct2/show/NCT00483574?term=MTA48&rank=1. Accessed December 16, 2011.
24. Maslanka SE, Gheesling LL, Libutti DE, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol. 1997;4:156-167. (Pubitemid 27130227)
25. Hou V, Bybel M, Hu B, et al. Meningococcal serum bactericidal assay using human complement. In: 11th European Monitoring Group on Meningococci (EMGM), Ljubjana, Slovenia, May 18-20, 2011.
26. Krah DL. Assays for antibodies to varicella-zoster virus. Infect Dis Clin North Am. 1996;10:507-527. (Pubitemid 26285285)
27. Williams V, Gershon A, Brunell PA. Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis. 1974;130:669-672.
28. Gershon A, Chen J, LaRussa P, et al. Varicella-zoster virus. In: Murray PR, Baron E, Jorgensen J, et al, eds. Manual of Clinical Microbiology. 9th ed. Washington, DC: ASM Press; 2007: 1537-1548.
29. Madore DV, Quataert SA, Vakevainen M. Quantitation of anti-pneumococcal capsular antibody in ligand-binding assays. In: Siber GR, Klugman K, Mäkelä PH, eds. Pneumococcal Vaccines: The Impact of Conjugate Vaccine. Washington, DC: ASM Press; 2008: 199-211.
30. Romero-Steiner S, Libutti D, Pais LB, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol. 1997;4:415-422. (Pubitemid 27321773)
31. Anderson P. Intrinsic tritium labeling of the capsular polysaccharide antigen of Haemophilus influenzae type B. J Immunol. 1978;120:866-870.
32. Norden CW, Michaels RH, Melish M. Serologic responses of children with meningitis due to Haemophilus influenzae type b. J Infect Dis. 1976;134:495-499.
33. World Health Organization (WHO) Web Site. WHO Expert Committee on Biological Standardization. Fourty-ninth Report. Available at: http://whqlibdoc. who.int/trs/WHO-TRS-897.pdf. Accessed December 13, 2011.
34. Keyserling HL, Pina M, Hou V, et al. Immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y, and W-135 (MCV-4) in 9- to 15-month olds. In: 44th Annual Meeting of the Infectious Disease Society of America (IDSA), Toronto, ON, Canada, October 12-15, 2006. Abstract 640.
35. Dagan R, Poolman J, Siegrist CA. Glycoconjugate vaccines and immune interference: A review. Vaccine. 2010;28:5513-5523.
36. Knuf M, Kieninger-Baum D, Habermehl P, et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine. 2010;28:744-753.
37. Snape MD, Perrett KP, Ford KJ, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA. 2008;299:173-184.
38. Borrow R, Aaberge IS, Santos GF, et al. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin Diagn Lab Immunol. 2005;12:970-976.
39. Richmond PC, Marshall HS, Nissen MD, et al. Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebocontrolled, phase 2 trial. Lancet Infect Dis. 2012;12:597-607.
40. Ortega-Sanchez I. Cost-effectiveness of meningococcal vaccination in infants and toddlers in the United States. Available at: http://www.cdc.gov/ vaccines/recs/acip/downloads/mtg-slides-oct11/03-MCV-Ortega-Sanchez. pdf. Accessed December 13, 2011.
41. Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009;27(suppl 2):B20-B29.
42. Bettinger JA, Scheifele DW, Le Saux N, et al.; Canadian Immunization Monitoring Program, Active (IMPACT). The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Pediatr Infect Dis J. 2009;28:220-224.
43. de Greeff SC, de Melker HE, Spanjaard L, et al. Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands. Pediatr Infect Dis J. 2006;25:79-80. (Pubitemid 43361483)